First-of-its kind FDA approved device designed for simplified, minimally invasive zone 2 TEVAR procedures. Maximize results without the potential risks and complexity of revascularization.

IDE Study outcomes. One year follow-up.

doctor showing nurse information on tablet

From pre-case planning to device procedural consultation, we are by your side to provide support. 

  • Training needs – Essential technical support with a deep reservoir of product knowledge.
  • 8+ years – Average field representatives’ tenure supporting Gore's aortic devices, building on diverse clinical backgrounds.
  • Non-commissioned sales force – Our focus is on outcomes.

Contact your Gore Field Sales Associate to learn more.

* For patients treated with TBE compared to those treated TEVAR and surgical LSA revascularization

  1. Squiers JJ, DiMaio JM, Schaffer JM, et al. Surgical debranching versus branched endografting in zone 2 thoracic endovascular aortic repair. Journal of Vascular Surgery 2022;75(6):1829-1836.e3.
  2. GORE® TAG® Thoracic Branch Endoprosthesis. [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc. 2022; MD184153. Rev. 1


21274900-EN thumbnail

Basic information about thoracic disease and treatment options for patients and their families

22495265-EN thumbnail

Overview of device, deployment, and primary benefits substantiated by data / outcomes for GORE® TAG® Thoracic Branch Endoprothesis.


GORE® TAG® Thoracic Branch Endoprothesis